Logo image of RCUS

ARCUS BIOSCIENCES INC (RCUS) Stock Fundamental Analysis

NYSE:RCUS - New York Stock Exchange, Inc. - US03969F1093 - Common Stock - Currency: USD

9.12  +0.5 (+5.8%)

After market: 9.12 0 (0%)

Fundamental Rating

3

RCUS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 567 industry peers in the Biotechnology industry. Both the profitability and financial health of RCUS have multiple concerns. RCUS is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RCUS had negative earnings in the past year.
RCUS had a negative operating cash flow in the past year.
RCUS had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: RCUS reported negative operating cash flow in multiple years.
RCUS Yearly Net Income VS EBIT VS OCF VS FCFRCUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

1.2 Ratios

RCUS has a better Return On Assets (-24.61%) than 72.61% of its industry peers.
Looking at the Return On Equity, with a value of -58.35%, RCUS is in the better half of the industry, outperforming 60.25% of the companies in the same industry.
Industry RankSector Rank
ROA -24.61%
ROE -58.35%
ROIC N/A
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
RCUS Yearly ROA, ROE, ROICRCUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RCUS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RCUS Yearly Profit, Operating, Gross MarginsRCUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

3

2. Health

2.1 Basic Checks

RCUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RCUS has been increased compared to 1 year ago.
The number of shares outstanding for RCUS has been increased compared to 5 years ago.
Compared to 1 year ago, RCUS has a worse debt to assets ratio.
RCUS Yearly Shares OutstandingRCUS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
RCUS Yearly Total Debt VS Total AssetsRCUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

RCUS has an Altman-Z score of -0.40. This is a bad value and indicates that RCUS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RCUS (-0.40) is better than 62.72% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that RCUS is not too dependend on debt financing.
RCUS's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. RCUS is outperformed by 65.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Altman-Z -0.4
ROIC/WACCN/A
WACC9.99%
RCUS Yearly LT Debt VS Equity VS FCFRCUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

2.3 Liquidity

A Current Ratio of 4.50 indicates that RCUS has no problem at all paying its short term obligations.
RCUS has a Current ratio (4.50) which is in line with its industry peers.
RCUS has a Quick Ratio of 4.50. This indicates that RCUS is financially healthy and has no problem in meeting its short term obligations.
RCUS has a Quick ratio (4.50) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.5
Quick Ratio 4.5
RCUS Yearly Current Assets VS Current LiabilitesRCUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

RCUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.30%, which is quite impressive.
The Revenue has grown by 120.51% in the past year. This is a very strong growth!
The Revenue has been growing by 76.65% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)25.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.63%
Revenue 1Y (TTM)120.51%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%-16.13%

3.2 Future

RCUS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.06% yearly.
The Revenue is expected to grow by 27.23% on average over the next years. This is a very strong growth
EPS Next Y-37.9%
EPS Next 2Y-18.58%
EPS Next 3Y-8.4%
EPS Next 5Y8.06%
Revenue Next Year-43.09%
Revenue Next 2Y-15.4%
Revenue Next 3Y-0.78%
Revenue Next 5Y27.23%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
RCUS Yearly Revenue VS EstimatesRCUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
RCUS Yearly EPS VS EstimatesRCUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RCUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RCUS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCUS Price Earnings VS Forward Price EarningsRCUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCUS Per share dataRCUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

RCUS's earnings are expected to decrease with -8.40% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-18.58%
EPS Next 3Y-8.4%

More info and screens

0

5. Dividend

5.1 Amount

RCUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARCUS BIOSCIENCES INC

NYSE:RCUS (5/2/2025, 8:20:02 PM)

After market: 9.12 0 (0%)

9.12

+0.5 (+5.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2025-02-25/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners94.92%
Inst Owner Change0.05%
Ins Owners6.49%
Ins Owner Change4.6%
Market Cap965.72M
Analysts82.11
Price Target30.97 (239.58%)
Short Float %9.65%
Short Ratio7.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.46%
Min EPS beat(2)7.78%
Max EPS beat(2)19.13%
EPS beat(4)4
Avg EPS beat(4)32.67%
Min EPS beat(4)7.78%
Max EPS beat(4)94.85%
EPS beat(8)7
Avg EPS beat(8)20.12%
EPS beat(12)10
Avg EPS beat(12)15.36%
EPS beat(16)11
Avg EPS beat(16)45.13%
Revenue beat(2)1
Avg Revenue beat(2)6.75%
Min Revenue beat(2)-11.8%
Max Revenue beat(2)25.3%
Revenue beat(4)3
Avg Revenue beat(4)95.65%
Min Revenue beat(4)-11.8%
Max Revenue beat(4)319.8%
Revenue beat(8)5
Avg Revenue beat(8)49.59%
Revenue beat(12)8
Avg Revenue beat(12)39.97%
Revenue beat(16)9
Avg Revenue beat(16)75.53%
PT rev (1m)-9.09%
PT rev (3m)-10.7%
EPS NQ rev (1m)-0.88%
EPS NQ rev (3m)13.73%
EPS NY rev (1m)-1.36%
EPS NY rev (3m)13.06%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-14.02%
Revenue NY rev (1m)-7.48%
Revenue NY rev (3m)-29.72%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.74
P/FCF N/A
P/OCF N/A
P/B 1.99
P/tB 1.99
EV/EBITDA N/A
EPS(TTM)-3.1
EYN/A
EPS(NY)-4.27
Fwd EYN/A
FCF(TTM)-1.66
FCFYN/A
OCF(TTM)-1.61
OCFYN/A
SpS2.44
BVpS4.58
TBVpS4.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.61%
ROE -58.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-24.17%
ROA(5y)-17.02%
ROE(3y)-55.15%
ROE(5y)-36.73%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.1
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 60%
Cap/Sales 2.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.5
Quick Ratio 4.5
Altman-Z -0.4
F-Score4
WACC9.99%
ROIC/WACCN/A
Cap/Depr(3y)153.33%
Cap/Depr(5y)249.37%
Cap/Sales(3y)9.4%
Cap/Sales(5y)7.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)25.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.63%
EPS Next Y-37.9%
EPS Next 2Y-18.58%
EPS Next 3Y-8.4%
EPS Next 5Y8.06%
Revenue 1Y (TTM)120.51%
Revenue growth 3Y-12.33%
Revenue growth 5Y76.65%
Sales Q2Q%-16.13%
Revenue Next Year-43.09%
Revenue Next 2Y-15.4%
Revenue Next 3Y-0.78%
Revenue Next 5Y27.23%
EBIT growth 1Y8.82%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.75%
EBIT Next 3Y-8.81%
EBIT Next 5YN/A
FCF growth 1Y46.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.44%
OCF growth 3YN/A
OCF growth 5YN/A